Mendus : Interim Report January - March 2024
English Swedish ...
Erik Manting Lotta Ferm Northx Biologics North Lymphoma Group Human Research Ethics Committee Northx Biologics
Source: marketscreener.com
📰 Lotta Ferm News
Lotta Ferm News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lotta Ferm. Real-time updates on events, politics, business and more.
Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX...
Source: marketscreener.com
Mendus to participate in multiple investor and industry conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023 Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare Confer...
Source: yahoo.com
Mendus AB: Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group
07.03.2023 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk ...
Source: wallstreet-online.de
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
Mario Brkulj Erik Manting Brendan Payne Society For Immunotherapy Of Cancer Valency Communications Year End Results
Source: finanznachrichten.de
Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
Mario Brkulj Erik Manting Brendan Payne Society For Immunotherapy Of Cancer Valency Communications Lotta Ferm
Source: finanznachrichten.de
Investegate |Immunicum AB Announcements | Immunicum AB: Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
Investegate announcements from Immunicum AB, Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
Mario Brkulj Erik Manting Brendan Payne Society For Immunotherapy Of Cancer Valency Communications Year End Results
Source: investegate.co.uk
Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
Mario Brkulj Erik Manting Brendan Payne Society For Immunotherapy Of Cancer Valency Communications Lotta Ferm
Source: finanznachrichten.de
Immunicum AB: Invitation to Immunicum's Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
10.02.2022 - Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth quarter and full year ended December 31, 2021 ...
Source: wallstreet-online.de
Immunicum AB: Invitation to Immunicum's Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth
Source: finanznachrichten.de